PVLA PALVELLA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1583648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-113.9%
TTM EPS YoY-120.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-63.4%
ROA-49.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio16.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-20.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $22.84M | $8.15M |
| SG&A expense | $15.76M | $5.94M |
| Operating income | -$38.60M | -$14.10M |
| Interest expense | $0 | $430,000 |
| Pretax income | -$41.72M | -$17.43M |
| Income tax | $0 | $0 |
| Net income | -$41.72M | -$17.43M |
| EPS (basic) | -3.71 | -7.83 |
| EPS (diluted) | -3.71 | -7.83 |
| Weighted avg. shares (diluted) | 11.25M | 2.23M |
| Banking | ||
| Net interest income | $2.59M | $642,000 |
| Balance sheet | ||
| Cash & equivalents | $57.98M | $83.60M |
| Short-term investments | $0 | — |
| Receivables | $0 | $358,000 |
| Current assets | $58.99M | $88.23M |
| Total assets | $59.56M | $88.23M |
| Current liabilities | $11.34M | $12.04M |
| Total liabilities | $31.58M | $25.63M |
| Shareholders' equity | $27.98M | $62.61M |
| Shares outstanding | 12.38M | 11.01M |
| Cash flow statement | ||
| Operating cash flow | -$25.01M | -$10.84M |
| Financing cash flow | -$660,000 | $87.09M |
| Stock-based compensation | $6.40M | $830,000 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.